Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug November 14, 2017 Encision, Inc. Reports Third Quarter Fiscal Year 2017 Results; Sequential Quarterly Revenue Grows 4 Percent February 7, 2017 AstraZeneca PLC Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial February 16, 2017
Encision, Inc. Reports Third Quarter Fiscal Year 2017 Results; Sequential Quarterly Revenue Grows 4 Percent February 7, 2017
AstraZeneca PLC Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial February 16, 2017